Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

2019-06 TRISCEND Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04221490
Recruitment Status : Recruiting
First Posted : January 9, 2020
Last Update Posted : December 3, 2020
Sponsor:
Information provided by (Responsible Party):
Edwards Lifesciences

Brief Summary:
Early feasibility study to assess safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

Condition or disease Intervention/treatment Phase
Tricuspid Valve Regurgitation Heart Valve Diseases Cardiovascular Diseases Device: Transcatheter Tricuspid Valve Replacement Not Applicable

Detailed Description:
The study is a multi-center, prospective, single arm study designed to evaluate the safety and performance of the Edwards EVOQUE Tricuspid Valve Replacement System

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Edwards Transcatheter Tricuspid Valve Replacement: Investigation of Safety and Clinical Efficacy Using a Novel Device
Actual Study Start Date : May 6, 2020
Estimated Primary Completion Date : October 2025
Estimated Study Completion Date : December 2025

Arm Intervention/treatment
Experimental: Treatment
Treatment with the Edwards EVOQUE Tricuspid Transcatheter Valve Replacement System
Device: Transcatheter Tricuspid Valve Replacement
Replacement of the tricuspid valve through a transcatheter approach
Other Name: Edwards EVOQUE Tricuspid Valve Replacement System




Primary Outcome Measures :
  1. Freedom from device or procedure-related adverse events [ Time Frame: 30 days ]
    Freedom from device or procedure-related adverse events


Secondary Outcome Measures :
  1. NYHA Functional Class [ Time Frame: 30 days, 6 months, 12 months, annual for five years ]
    Number of patients with improvement in NYHA class

  2. Six minute walk test [ Time Frame: 30 days, 6 months, 12 months, annual for five years ]
    Change in distance (m) from baseline

  3. Reduction in TR grade [ Time Frame: 30 days, 6 months, 12 months, annual for five years ]
    Number of patients with reduction in TR from baseline

  4. Health Status - KCCQ [ Time Frame: 30 days, 6 months, 12 months, annual for five years ]
    Number of points of improvement in health status as measured by Kansas City Cardiomyopathy Questionnaire

  5. Health Status - SF-36 [ Time Frame: 30 days, 6 months, 12 months, annual for five years ]
    Number of points of improvement in health status as measured by 36 item short form survey (SF-36)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Functional or degenerative TR moderate or greater
  • Symptomatic despite medical therapy
  • The Local Site Heart Team determines that the patient is appropriate for transcatheter tricuspid valve replacement

Exclusion Criteria:

  • Unsuitable anatomy
  • Previous tricuspid valve repair or replacement
  • Comorbid condition(s) that, in the opinion of the investigator, could limit the patient's ability to participate in the study, including compliance with follow- up requirements, or that could impact the scientific integrity of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04221490


Contacts
Layout table for location contacts
Contact: TMTT Clinical 949-250-2500 TMTT_Clinical@Edwards.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
Edwards Lifesciences
Investigators
Layout table for investigator information
Principal Investigator: Susheel Kodali, MD Columbia University
Layout table for additonal information
Responsible Party: Edwards Lifesciences
ClinicalTrials.gov Identifier: NCT04221490    
Other Study ID Numbers: 2019-06
First Posted: January 9, 2020    Key Record Dates
Last Update Posted: December 3, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Edwards Lifesciences:
Tricuspid Regurgitation
Transcatheter
Replacement
Functional
Degenerative
Regurgitation
Valve Replacement
Cardiovascular Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Heart Valve Diseases
Tricuspid Valve Insufficiency
Heart Diseases